ClinicalTrials.gg
CompletedNCT07566455Updated May 5, 2026

Comparing Intra-Umbilical Versus Intravenous Oxytocin in Women During the Third Stage of Labor for Reducing Blood Loss

A Phase 4 interventional study of Oxytocin after delivery and Intraumbilical oxytocin in Postpartum Bleeding, Oxytocin and Third Stage of Labour, sponsored by CMH Multan Institute of Medical Sciences. Completed at 1 site in Pakistan. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by CMH Multan Institute of Medical Sciences · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2025, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Postpartum Hemorrhage with a site in Pakistan — 4 open to participants now, 4 under way, none of them phase 3. Postpartum Hemorrhage · Pakistan.

Enrollment
13th of 16
60 · median 181
Started
2025
with 1 other
Phase 4
Only one
of the 17
Registered
15th of 17
by date
Lead sponsor
1 of 17
CMH Multan Institute of Medical Sciences

Among the 17 studies in Postpartum Hemorrhage with a site in Pakistan, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 4, and was the 15th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

4 of the 17 studies in Postpartum Hemorrhage with a site in Pakistan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Postpartum Hemorrhage with a site in Pakistan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether giving oxytocin through the umbilical cord is more effective than giving it through a vein in reducing blood loss during the third stage of labor. The third stage of labor is the period between the birth of the baby and the delivery of the placenta. Excessive bleeding after delivery, known as postpartum hemorrhage, is a major cause of maternal illness and death worldwide. Oxytocin is commonly used to help the uterus contract and reduce bleeding after childbirth.

The main question this study aims to answer is:

Does intra-umbilical oxytocin reduce the average amount of blood loss during the third stage of labor compared with intravenous oxytocin?

Researchers will conduct a randomized controlled trial involving 60 women with uncomplicated pregnancies who are in spontaneous labor. Participants will be randomly assigned to one of two groups.

Participants in the first group will receive 10 IU oxytocin intravenously at the delivery of the baby's anterior shoulder. Participants in the second group will receive 10 IU oxytocin injected into the umbilical cord after the baby is delivered.

In both groups, the placenta will be delivered using controlled cord traction. Blood loss will be measured by collecting blood in a kidney tray and by weighing pre-weighed sanitary pads for the first 24 hours after delivery.

Researchers will compare the average blood loss between the two groups to determine which method of administering oxytocin is more effective in reducing postpartum bleeding.

03

Conditions studied

  • Postpartum Bleeding
  • Oxytocin
  • Third Stage of Labour

Browse trials for

Keywords

  • Intravenous oxytocin
  • intra umbilical oxytocin
  • postpartum hemorrhage
  • third stage of labour
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age 36 - 42 weeks (on LMP)
  • In spontaneous labour

Exclusion criteria

Exclusion Criteria:

  • Chronic hypertension
  • Pre-eclampsia
  • Multiple pregnancies
  • Preterm or postdates pregnancy
  • Previous cesarean section
  • Diabetes (chronic and gestational)
  • Fetal macrosomia
  • History of bleeding / clotting disorder
  • History of anti-coagulation heparin / warfarin therapy
  • Non-reassuring cardiotocograph or poor progress of labour
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Intravenous Oxytocin

    Women in this group will receive 10 IU oxytocin administered intravenously at the delivery of the anterior shoulder of the baby during the third stage of labor.

    Drug: Oxytocin after delivery

  • Experimental
    Intraumbilical Oxytocin

    Women in this group will receive 10 IU oxytocin administered through the umbilical vein after delivery of the baby during the third stage of labor.

    Drug: Intraumbilical oxytocin

Interventions

  • DrugOxytocin after delivery

    10 IU oxytocin diluted in normal saline administered slowly via intravenous route at the time of delivery of the anterior shoulder to facilitate uterine contraction and reduce blood loss.

  • DrugIntraumbilical oxytocin

    10 IU oxytocin diluted in 10 mL normal saline injected into the umbilical vein approximately 2 cm from the introitus after delivery of the baby, with the solution gently milked toward the placental insertion to promote placental separation and reduce blood loss.

06

What researchers measure

Primary outcomes

  1. Mean Blood Loss During the Third Stage of Labor and Within the First 24 Hours After Vaginal Delivery

    The average amount of blood lost after delivery will be measured in milliliters. Blood loss will be collected in a kidney tray immediately after delivery and quantified using a graduated cylinder. Additional blood loss during the first 24 hours postpartum will be measured using pre-weighed sanitary pads (1 gram weight increase = 1 mL blood loss).

    Time frame: From delivery of the baby until 24 hours postpartum

07

Study locations

1 site
  • CMH Multan Institute of Medical Sciences
    Multan, Punjab Province 60000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Feb 2026, 5 months.

Of 28 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 29 studies reached it within 12 months; a quarter within 10 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 5, 2026
StartActual
Aug 13, 2025
Primary completionActual
Feb 12, 2026
CompletionActual
Feb 12, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566455
Lead sponsor
CMH Multan Institute of Medical Sciences
Responsible party
Dr. Sana Siddique (Principle Investigator, CMH Multan Institute of Medical Sciences) — Principal investigator
First posted
May 5, 2026
Start date
Aug 13, 2025
Primary completion
Feb 12, 2026
Completion
Feb 12, 2026
Last update
May 5, 2026

Study contacts

Nidda Y Assistant Professor, FCPS
study chair · CMH Multan Institute of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion